Alydia Health is focused on preventing maternal morbidity and mortality caused by postpartum hemorrhage (PPH) and abnormal postpartum uterine bleeding. Founded in 2010 and based in Menlo Park, Calif., the company’s investigational Jada System is designed to work with normal uterine contractions to rapidly stop excessive bleeding after childbirth. Alydia completed the pivotal PEARLE IDE Study and has submitted results in a pending 510(k) to the U.S. Food and Drug Administration seeking marketing clearance. The company announced a $13.9 million Series C to support the anticipated U.S. commercial launch of the Jada System. PPH is described in the filing as one of the most common complications of birth, leading to pharmacologic treatment in up to 10% of mothers and, in some cases, emergency interventions and maternal death. Alydia positions the Jada System as a potential tool to improve outcomes for mothers and families globally. Alydia Health is a privately held, venture-backed medical device company headquartered in Menlo Park, Calif., developing an investigational device to rapidly stop postpartum hemorrhage by encouraging the uterus to contract. The device concept was developed in 2010 at Cal Poly and the company was formerly known as InPress Technologies. In a published pilot study of 10 patients in Obstetrics & Gynecology, the device controlled hemorrhage within minutes for each mother. Alydia has initiated the PEARLE Study to evaluate safety and effectiveness in 107 U.S. deliveries to support a planned 510(k) submission to the U.S. Food and Drug Administration. The company says the new funding will support the U.S. pivotal study and subsequent steps toward commercialization. Alydia is positioning its product as a physiologic, rapid-response option for managing a leading cause of maternal morbidity and mortality.

Total raised

$24M

Funding rounds

2

Latest round

Series C

Latest activity

Jul 2020